No Data
No Data
Neuphoria Releases Review Of 2024 And Highlights 2025 Plans Including $15M Payment From Merck Extending Company's Cash Runway To Q3 2026 And Phase 3 Affirm-1 Trial of BNC210 In Social Anxiety Disorder Progressing As Planned With Topline Readout...
Neuphoria Provides a Review of 2024 and Highlights 2025 Plans
Express News | Neuphoria Therapeutics Inc : Maxim Group Cuts Target Price to $18 From $48
Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025
Neuphoria Therapeutics | 10-Q: Q2 2025 Earnings Report
Pre-Hour Trading Sees Neuphoria (NEUP) Stock Surge